Stockscreener 앱 받기
6.36
7.56%
-0.52
시간 외 거래:
6.31
-0.05
-0.79%
전일 마감가:
$6.88
열려 있는:
$6.67
하루 거래량:
413.99K
Relative Volume:
0.74
시가총액:
$275.04M
수익:
-
순이익/손실:
$-110.66M
주가수익비율:
-2.0541
EPS:
-3.0963
순현금흐름:
$-97.76M
1주 성능:
-16.43%
1개월 성능:
+15.22%
6개월 성능:
+178.95%
1년 성능:
+23.26%
1일 변동 폭
$6.30
$6.93
1주일 범위
$6.30
$8.11
52주 변동 폭
$1.78
$8.4471
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
명칭
Kyverna Therapeutics Inc
전화
(510) 626-8331
주소
5980 HORTON STREET, EMERYVILLE
KYTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
6.36 | 297.53M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-05-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-03 | 개시 | H.C. Wainwright | Neutral |
| 2024-03-04 | 개시 | JP Morgan | Overweight |
| 2024-03-04 | 개시 | Leerink Partners | Outperform |
| 2024-03-04 | 개시 | Morgan Stanley | Overweight |
| 2024-03-04 | 개시 | Wells Fargo | Overweight |
모두보기
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Kyverna secures $150 million loan facility to advance autoimmune therapies By Investing.com - Investing.com Australia
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Patterns & Technical Confirmation Trade Alerts - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsEarnings Trend Report & Daily Growth Stock Tips - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedQuarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Growth vs Value & Real-Time Volume Triggers - newser.com
Pattern recognition hints at Kyverna Therapeutics Inc. upside2025 Market Outlook & Verified Short-Term Trading Plans - newser.com
Kyverna secures $150 million loan facility to advance autoimmune therapies - Investing.com
Kyverna Therapeutics Secures $150 Million Loan Facility - TipRanks
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - The Manila Times
[8-K] Kyverna Therapeutics, Inc. Reports Material Event | KYTX SEC FilingForm 8-K - Stock Titan
Kyverna (Nasdaq: KYTX) secures up to $150M non-dilutive financing maturing 2030 - Stock Titan
Using economic indicators to assess Kyverna Therapeutics Inc. potentialJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
How sentiment analysis helps forecast Kyverna Therapeutics Inc.CEO Change & Safe Capital Preservation Plans - newser.com
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - MSN
Will Kyverna Therapeutics Inc. stock deliver long term returnsMarket Growth Review & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Kyverna Therapeutics Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com
Can machine learning forecast Kyverna Therapeutics Inc. recoveryTrade Entry Summary & High Accuracy Trade Alerts - newser.com
Is Kyverna Therapeutics Inc. stock a buy before product launchesTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
Kyverna Therapeutics, Inc. (KYTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101 - TipRanks
What is HC Wainwright's Estimate for KYTX Q3 Earnings? - MarketBeat
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy - MSN
Kyverna’s CAR T Therapy Sets 'New Efficacy Standard' in Myasthenia Gravis, De-Risking Phase III Trials - BioSpace
Amen at AANEM: Kyverna makes good on MG phase II promise - BioWorld MedTech
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data - TipRanks
Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com - Investing.com Canada
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - The Manila Times
Kyverna Therapeutics Reports Promising Interim Results from Phase 2 Trial of KYV-101 in Generalized Myasthenia Gravis, Setting a New Clinical Standard - Quiver Quantitative
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study - TradingView
Kyverna Therapeutics announces positive interim phase 2 data from KYSA-6 study of KYV-101 in generalized Myasthenia gravis at AANEM 2025 - MarketScreener
Kyverna KYTX shares Phase 2 interim KYV-101 results in gMG update - Stock Titan
Kyverna (Nasdaq: KYTX): 100% MG-ADL and QMG response in gMG Phase 2; no ICANS - Stock Titan
How strong is Kyverna Therapeutics Inc. stock balance sheet2025 Year in Review & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Kyverna Therapeutics Inc (KYTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):